Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Onconetix, Inc. (ONCO)
USD0.77
-0.08 (-8.84%)
US NASDAQ Healthcare Biotechnology
Address
201 East Fifth Street 45202
Cincinnati, OH, US
Cincinnati, OH, US
CEO
David Allan White
Website
onconetix.gcs-web.com
IPO
2022-02-18
CIK 1782107 ISIN US68237Q4010
Also trades on
NASDAQ Capital Market · BWV (USD)
NASDAQ Capital Market · ONCO (USD)
Description
Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH). In its development pipeline, Onconetix is advancing a Streptococcus pneumoniae vaccine candidate, designed to prevent infectious middle ear infections in children and pneumonia in the elderly. Additionally, they are working on a universal influenza vaccine intended to provide comprehensive protection against all aggressive strains of the flu virus. Furthermore, Onconetix holds a license for an advanced norovirus S&P nanoparticle virus-like particle (VLP) vaccine platform from Cincinnati Children's. This adaptable platform is being leveraged to create vaccines for various infectious diseases, such as Marburg and monkeypox, among others. Established in 2018, the company was previously known as Blue Water Biotech, Inc., before changing its name to Onconetix, Inc. in December 2023. Its corporate headquarters are located in Cincinnati, Ohio.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.77
-0.08 (-8.84%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
2.72
Float Shares
1.44M
Free Float %
42.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.42% | -9.38% | -62.59% | -92.31% | -97.03% | -94.77% | -98.63% | -100.00% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
0.77
DCF (Unlevered)
1.38
+78.1%
DCF (Levered)
1.41
+82.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-10.08
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-67.7% Q1'26: -78.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+99.1% ★ Q1'26: +98.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,165.2% Q1'26: -9,887.1% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-778.2% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-59.9% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2,803.1% Q1'26: -16.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
58.5K
est: 58.0K (+0.8%)
|
2.52M
est: 800.0K (+215.5%)
|
815.4K
est: 815.4K (+0.0%)
|
881.2K
881.2K – 881.2K
+8.1% YoY
|
952.4K
952.4K – 952.4K
+8.1% YoY
|
| EBITDA |
-36.71M
est: 11.6K (-316,564.6%)
|
-57.60M
est: -160.0K (-35,898.5%)
|
-6.33M
est: -163.1K (-3,781.5%)
|
-176.2K
-176.2K – -176.2K
-8.1% YoY
|
-190.5K
-190.5K – -190.5K
-8.1% YoY
|
| EBIT |
-36.75M
est: 11.6K (-316,943.4%)
|
-58.33M
est: -160.0K (-36,355.6%)
|
-6.34M
est: -163.1K (-3,790.8%)
|
-176.2K
-176.2K – -176.2K
-8.1% YoY
|
-190.5K
-190.5K – -190.5K
-8.1% YoY
|
| Net Income |
-37.41M
est: -83.47M (+55.2%)
|
-58.69M
est: -47.42B (+99.9%)
|
-14.03M
est: -55.23B (+100.0%)
|
-65.84B
-65.84B – -65.84B
-19.2% YoY
|
-70.30B
-70.30B – -70.30B
-6.8% YoY
|
| SGA |
14.77M
est: 3.02M (+389.6%)
|
11.23M
est: 42.84M (-73.8%)
|
7.04M
est: 43.66M (-83.9%)
|
47.19M
47.19M – 47.19M
+8.1% YoY
|
51.00M
51.00M – 51.00M
+8.1% YoY
|
| EPS |
-25.03
est: -2,584.00 (+99.0%)
|
-520.93
est: -14,450.00 (+96.4%)
|
-4.73
est: -16,830.00 (+100.0%)
|
-20,060.00
-20,060.00 – -20,060.00
-19.2% YoY
|
-21,420.00
-21,420.00 – -21,420.00
-6.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-06 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-05 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-9.94M
OE per share TTM
-5.17
Owner's Yield
-753.43%
Maintenance CapEx ratio
1.11%
Maint CapEx / Avg PPE
15.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
3
Beneficial owners (>5%)
5
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Altos Venture AG | 2.70M | 32.50% | 2.70M | — | 2.70M | — | CO | — | 2024-09-26 | ↗ |
| 2 | New Horizon Health Limited | 573.1K | 6.91% | 573.1K | — | 573.1K | — | CO | Cayman Islands | 2024-09-26 | ↗ |
| 3 | Zurcher Kantonalbank | 562.7K | 6.80% | 562.7K | — | 562.7K | — | FI | Switzerland | 2024-11-14 | ↗ |
| 4 | Ralph Schiess | 495.9K | 5.98% | 495.9K | — | 495.9K | — | IN | Switzerland | 2024-10-01 | ↗ |
| 5 | Christian Bruhlmann | 433.9K | 5.23% | 433.9K | — | 433.9K | — | IN | Switzerland | 2024-10-01 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
1.02
Neutral
Buys
3
Sells
3
Shares acquired
201.5K
Shares disposed
198.0K
Cash buys
3.00
Cash sales
3.00
Net activity
+3,501
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-21 | HRT FINANCIAL LP | 10% Owner | S-Sale | D | Class A Shares | 49,710 | 0.69 | 34.3K | 33,649 | D | ↗ |
| 2026-04-20 | HRT FINANCIAL LP | 10% Owner | S-Sale | D | Class A Shares | 94,462 | 0.75 | 70.8K | 83,359 | D | ↗ |
| 2026-04-17 | HRT FINANCIAL LP | 10% Owner | P-Purchase | A | Class A Shares | 34,636 | 0.73 | 25.3K | 177,821 | D | ↗ |
| 2026-04-16 | HRT FINANCIAL LP | 10% Owner | S-Sale | D | Class A Shares | 53,867 | 0.73 | 39.3K | 143,185 | D | ↗ |
| 2026-04-15 | HRT FINANCIAL LP | 10% Owner | P-Purchase | A | Class A Shares | 92,554 | 0.76 | 70.3K | 197,052 | D | ↗ |
| 2026-04-14 | HRT FINANCIAL LP | 10% Owner | — | — | Class A Shares | 0 | 0.00 | — | 104,498 | D | ↗ |
| 2026-03-19 | DORF SAMMY | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | White David Allan | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-12-05 | Romano Sarah | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-15 | Tarsh Simon | Director | A-Award | A | Common Stock | 618 | 0.00 | — | 658 | D | ↗ |
| 2025-08-15 | Ramdeen Timothy R. | Director | J-Other | A | Common Stock | 39 | 0.00 | — | 40 | D | ↗ |
| 2025-08-15 | Oakley Andrew John | Director | A-Award | A | Common Stock | 618 | 0.00 | — | 638 | D | ↗ |
| 2025-08-15 | Meier Thomas | Director | A-Award | A | Common Stock | 618 | 0.00 | — | 657 | D | ↗ |
| 2025-07-14 | Altos Venture AG | 10% Owner | J-Other | A | Common Stock | 241,514 | 0.00 | — | 273,230 | D | ↗ |
| 2025-06-23 | Altos Venture AG | 10% Owner | — | — | Make-whole right (right to acquire) | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-03-23 | Oakley Andrew John | Director | A-Award | A | Common Stock | 1,709 | 0.00 | — | 1,709 | D | ↗ |
| 2025-02-24 | Oakley Andrew John | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-20 | Schiess Ralph | Officer | A-Award | A | Common Stock | 177,462 | 0.00 | — | 673,365 | D | ↗ |
| 2024-12-20 | Bruhlmann Christian | Officer | A-Award | A | Common Stock | 177,462 | 0.00 | — | 611,372 | D | ↗ |
| 2024-09-26 | Tarsh Simon | Director | A-Award | A | Common Stock | 3,318 | 0.00 | — | 3,477 | D | ↗ |
| 2024-09-26 | SINGH AJIT | Director | A-Award | A | Common Stock | 3,318 | 0.00 | — | 3,396 | D | ↗ |
| 2024-09-26 | SAPIRSTEIN JAMES | Director | A-Award | A | Common Stock | 3,318 | 0.00 | — | 3,477 | D | ↗ |
| 2024-09-26 | Ramdeen Timothy R. | Director | A-Award | A | Common Stock | 3,318 | 0.00 | — | 3,477 | D | ↗ |
| 2024-09-26 | Meier Thomas | Director | A-Award | A | Common Stock | 3,318 | 0.00 | — | 3,318 | D | ↗ |
| 2024-09-24 | Schiess Ralph | Officer | A-Award | A | Common Stock | 489,160 | 0.00 | — | 495,903 | D | ↗ |
| 2024-09-24 | Bruhlmann Christian | Officer | A-Award | A | Common Stock | 428,010 | 0.00 | — | 433,910 | D | ↗ |
| 2024-09-24 | Altos Venture AG | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 2,695,931 | D | ↗ |
| 2024-06-10 | FEDASZ KARINA M | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-16 | SINGH AJIT | Director | A-Award | A | Common Stock | 3,125 | 0.00 | — | 3,125 | — | ↗ |
| 2024-02-08 | SINGH AJIT | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-06 | Meier Thomas | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-12-05 | LIBERTY MEDIA CORP /DE/ | 10% Owner | J-Other | D | Common Stock | 22,897,677 | 0.00 | — | 7,924,663 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-5.3K
Shares Outstanding
3.43M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Karina Fedasz | Interim Chief Financial Officer | 352.1K | female |
| Brian Price | Head of Technology Strategy | 126.5K | — |
| Ali I. Fattom | Head of Science & Discovery | — | — |
| Jay Newmark | Chief Medical Officer | — | — |
| Theodore Scott Yoho | Head of Business Development | — | male |
| David Allan White | Chief Executive Officer | — | male |
| Andrew D. Skibo | Global Head of Biologics Operations | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ONCO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
